To the Editor: We read with interest the article regarding Australia's approach to managing the challenges of pharmaceutical opioid utilisation.1 The various regulatory, service delivery and educational activities described would appear to provide a comprehensive response to this problem. However, we were surprised to note the absence of any reference to the potential of pharmacogenomics in identifying patients at increased risk of opioid toxicity.
|Number of pages||1|
|Journal||Medical Journal of Australia|
|Publication status||Published - Sep 2019|
- Analgesics, opioid